TuHURA Biosciences Reports REM-001 Meets Safety Endpoint in Metastatic Breast Cancer Trial
I'm PortAI, I can summarize articles.
TuHURA Biosciences Inc. announced that its REM-001 clinical trial for metastatic breast cancer met its primary safety endpoint, showing clinical efficacy. This milestone triggers the release of 1,539,958 shares to legacy Kintara Therapeutics stockholders, as per the Contingent Value Rights Agreement. The shares will be distributed within ten business days. Results have been presented, and the news was originally published by TuHURA via PR Newswire.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments